Yeast-leavened oat breads with high or low molecular weight β-glucan do not differ in their effects on blood concentrations of lipids, insulin, or glucose in humans

被引:62
作者
Frank, J [1 ]
Sundberg, B
Kamal-Eldin, A
Vessby, B
Åman, P
机构
[1] Swedish Univ Agr Sci, Dept Food Sci, S-75007 Uppsala, Sweden
[2] Uppsala Univ, Dept Publ Hlth & Caring Sci, Clin Nutr Res Unit, S-75125 Uppsala, Sweden
关键词
beta-glucan; oat bran bread; soluble fiber; blood lipids; humans;
D O I
10.1093/jn/134.6.1384
中图分类号
R15 [营养卫生、食品卫生]; TS201 [基础科学];
学科分类号
100403 ;
摘要
Increased intestinal viscosity appears to be the major mode of action by which dietary oat P-glucan increases the fecal excretion of bile acids and thereby lowers blood cholesterol concentrations. The objective of this experiment was to investigate whether there is a difference in effects on blood lipids between two yeast-leavened oat bran breads containing beta-glucan (6 g/d) of low or high average molecular weight (HMW) (217 or 797 kDa, respectively). The breads were fed to 22 volunteers (women, n = 11; men, n = 11) in a randomized, double-blind, crossover design. The participants ate one bread for 3 wk as part of their normal diet and switched breads after a 2-wk washout period. Blood samples were drawn from fasting subjects and analyzed for lipids, insulin, glucose, and alpha- and gamma-tocopherol. The two experimental oat breads did not differ in their effects on any of the variables measured. Compared to baseline, however, consumption of HMW bread increased serum insulin by 22.6% (P < 0.03) and decreased blood glucose concentrations by 3.4% (P < 0.05). These results suggest that the molecular weight, when beta-glucan is consumed in oat bran breads as part of the habitual diet, does not play an important physiological role in moderately hypercholesterolemic humans.
引用
收藏
页码:1384 / 1388
页数:5
相关论文
共 25 条
[21]  
SEIGLER L, 1981, CLIN CHEM, V27, P838
[22]  
TIETYEN J L, 1990, FASEB Journal, V4, pA527
[23]   Cereal grains and coronary heart disease [J].
Truswell, AS .
EUROPEAN JOURNAL OF CLINICAL NUTRITION, 2002, 56 (01) :1-14
[24]  
*US FDA, 1997, FED REGISTER, V62, P3584
[25]  
UUSITUPA MIJ, 1992, J AM COLL NUTR, V11, P651